Characterization of a whole, inactivated influenza (H5N1) vaccine

Influenza and other Respiratory Viruses

Volumn 2, Issue 6, 2008, Pages 261-266

  Tada, Yoshikazu ^a  

^a Osaka University   (Japan)

Author keywords

Aluminum hydroxide adjuvant; Inactivated whole virion; Influenza; Pandemic; Reverse genetics; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; UNCLASSIFIED DRUG;

ADSORPTION; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE WARMTH; MALE; NASAL DRAINAGE; NONHUMAN; NORMAL HUMAN; NOSE DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRODUCTIVITY; PRURITUS; QUALITY CONTROL; SKIN REDNESS; SWELLING; SYSTEMIC DISEASE; VACCINE PRODUCTION; VIRUS STRAIN; WEARINESS; ANIMAL; CHICK EMBRYO; IMMUNOLOGY; JAPAN; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANIMALS; CHICK EMBRYO; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; JAPAN; MALE; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 66449095061     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00054.x     Document Type: Article

References (17)

1. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO, 13 February 2006. Available at: http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2008_06_19/en/index.html (accessed 14 August 2008).
2. Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenaza A (H5N1) N. Engl J Med 2005;352:333-340.
3. Nicholson KG, Colegate AE, Podda A. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trail of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-1943.
4. Stephenson I, Nicholson KG, Gluck R et al. Safety and antigenicity of whole virus and subunit influenza A/Hon Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomised trial. Lancet 2003;362:1959-1966.
5. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent aluminium-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004;103:163-171.
6. Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006;43:1135-1142.
7. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004(H5N1) vaccine: phase I randomized trial. Lancet 2006;367:1657-1664.
8. Lin J, Zhang J, Dong X. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised controlled trial. Lancet 2006;368:991-997.
9. WHO. Tables on the Clinical Trials of Pandemic Influenza Prototype Vaccines. Available at: http://www.who.int/vaccine_research/diseases/ influenza/flu_trials_tables/en/index.html (accessed 14 August 2008).
10. WHO. Antigenic and Genetic Characteristics of H5N1 Viruses and Candidate H5N1 Vaccine Viruses Developed for Potential Use as Pre-pandemic Vaccines. Available at: http://www.who.int./wer/2007/wer8219.pdf (accessed 26 November 2008).
11. Wood JM, Robertson JS. From lethal virus to life-saving vaccine development inactivated vaccines for pandemic influenza. Nat Rev Microbial 2004;2:842-847.
12. WHO. WHO Technical Report Series, No. 941, 2007, Annex 5 Biosafety Risk Assessment and Guidelines for the Production and Quality Control of Human Influenza Pandemic Vaccines (Established by ECBS, 28 Oct 05), 2008. Available at: http://www.who.int/biologicals/publications/trs/ areas/vaccines/influenza/en/index.html (accessed 26 November 2008).
13. WHO. WHO Technical Report Series, No. 927, 2005, Annex 3 Recommendations for The Production and Control of Influenza Vaccine (inactivated). Available at: http://www.who.int/biologicals/publications/trs/areas/ vaccines/influenza/en/index.html (accessed 26 November 2008).
14. European Directorate for the Quality of Medicine. European Pharmacopoeia. 5th edn. Vol. 1 Vaccines, Influenza Vaccine (Whole Virion Inactivated) 2005. Council of Europe: Strasbourg Cedex 1, France, 676-678.
15. National Institute of Infectious Diseases. Minimum Requirements for Biological Products. Japan: National Institute of Infectious Diseases, 2006. General Tests, 272-336 and Influenza Vaccine, 10-13.
16. Society of Japanese Pharmacopoeia. The Japanese Pharmacopoeia Fifteenth Edition (JP XV). Tokyo. General Tests, Process and Apparatus, 106-113.
17. FDA, HHS. International Conference on Harmonization; Final Guideline on Stability Testing of Biotechnological/Biological Products, Availability. 1996. Federal Register, Vol. 61, No. 133/Wednesday, 10 July 1996, Notices: 36466-36469.